The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,700.00
Ask: 1,810.00
Change: 0.00 (0.00%)
Spread: 110.00 (6.471%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

INSIGHT-Currency drop hits Egypt's medicine supplies, angering public

Tue, 22nd Nov 2016 13:27

* Pharma companies halting imports of drugs after currencyfloat

* Govt unwilling to ease price controls, deepening shortages

* Companies say govt plan to subsidise key drugsinsufficient

* Black market springs up

By Arwa Gaballa and Eric Knecht

CAIRO, Nov 22 (Reuters) - Pharmacies across Egypt arerunning short of medicines, some of them life-savers, as aplunge in the value of the Egyptian pound coupled with strictgovernment price caps has made scores of products unprofitableto produce or import.

The shortages include some cancer treatments as well asbasic items like insulin, tetanus shots and contraceptive pills.

Unable to raise prices above levels set by the HealthMinistry but now paying roughly twice as much to import drugs oractive ingredients, pharmaceutical firms say they have beenforced to phase out certain medicine to stay in business.

"We aren't a charity. We have expenses and production costs,and if a company isn't making profit it will have to haltproduction," said Said Ibrahim, factory manager at EIPICO, oneof Egypt's largest pharmaceutical companies.

That brings no comfort to pharmacists and sick Egyptians.

Out of insulin for weeks, Ali Etman said he was recentlyforced to turn away eight diabetes patients from his Cairopharmacy in a single day.

"Patients who come looking for insulin ask me: 'What am Isupposed to do? Die?' and I don't know what to tell them. Idon't have the drugs they need," Etman said.

Egypt floated its currency on Nov. 3, abandoning a peg of8.8 pounds to the U.S. dollar and allowing the currency toroughly halve in value to about 17.50 on Tuesday.

The float helped the cash-strapped government clinch a $12billion IMF loan it hopes will unlock investment and revivegrowth that has been hampered by political uncertainty since the2011 uprising that toppled President Hosni Mubarak.

But the medicine shortages are piling pressure on thegovernment of general-turned-president Abdel Fattah al-Sisi, whohas been at pains to reassure a populace already strugglng withdouble-digit inflation and intermittent shortages that theywould be shielded from the worst effects of economic reforms.

Talk of a looming healthcare crisis has dominated popularevening chatshows, with doctors calling in nightly to reportrapidly depleting stocks and patients being turned away fromhospitals for lack of supplies.

The Health Ministry has blamed the problem on panickingEgyptians hoarding medicines and said it would not raise prices.

Drug shortages are not new to Egypt. More medicines hadalready begun disappearing from shelves early this year as asevere shortage of dollars in the banks meant pharmaceuticalfirms could not pay for the necessary imports.

Egypt has struggled to earn enough dollars since the 2011uprising scared off foreign investors and tourists and thecentral bank drained its reserves defending the currency peg.

The Health Ministry set up a Drug Shortages Directorate in2012 to minimise the impact by suggesting suitable substitutesfor missing medicines. But the situation has only worsened.

EIPICO's vice president told Reuters about 1,600 drugs hadgone short in recent months, including 35 that have noalternatives and would disappear from the market if price capswere not eased.

"Distributors are now telling pharmacies nothing imported isavailable. The problem has been going on for a while, but hasonly turned into a crisis in recent weeks," Etman said.

SITUATION WORSENING

Egypt's drugs market is 40 percent multinational - bigsuppliers include Pfizer, Novartis,GlaxoSmithKline and Sanofi - and 60 percentdomestic. Nearly all of it is in private hands, with annualsales worth a total of about 50 billion pounds before the float.

Ahmed al-Ezaby, head of the medicine industry division atFederation of Egyptian Industries, said Egypt imports about $600million in finished medicines per year and $1.8 billion inactive ingredients.

Officials at multinationals said they were concerned at theworsening situation. One industry source said companies were nowin talks with Egyptian ministries on the possibility ofrestoring some prices to pre-Nov. 3 levels, in dollar terms, toensure supplies of the most critical medicines.

The multinationals have local factories set up but 15-20percent of drugs are imported, while 80-85 percent are producedlocally. About 70 percent of all drugs in Egypt are generic anddomestic-made.

A spokesman for Sanofi said the French group was "activelyengaging local authorities to define a sustainable pricingmechanism".

Egypt's supply problems echo those in Venezuela, where alack of dollars has also created drug shortages and leftmanufacturers nursing big losses.

Before the flotation, Egypt faced a dollar shortage that sawimported goods ranging from electronic equipment to sugardisappear briefly from shelves in the past year.

The central bank rationed supplies via weekly auctions,earmarking the little it had for essential items like medicine.

Dollar supply is less of an issue since the flotation. Butthe cost of buying the greenback is because companies importactive ingredients they need to make generic medicines.

The government, which already raised prices on a slew ofmedicines this year, is under pressure to keep drugs affordablefor tens of millions of poor Egyptians.

It has blamed the crisis on hoarding and greed.

"It's an orchestrated crisis. The decision to float thepound was taken...and two hours later people began saying wehave a crisis and we don't have meds," Health Ministry spokesmanKhaled Mogahed told the Egyptian TV channel Mehwar.

"It's a way to push for a rise in medicine prices, whichwill not happen."

Mogahed did not respond to requests from Reuters forcomment.

The companies want the government to remove the price capsentirely or re-adjust them to ease their losses.

The Health Ministry met last week with drug industry leadersto discuss an emergency plan. It has offered to subsidisepharmaceutical companies to the tune of $165 million to supportimports of life-saving drugs that have no viable substitutes,including some cancer treatments.

Companies said the amount was not nearly enough whilerolling out a new subsidy programme would take time.

"There's no way of knowing how long this amount will lastbecause cancer drugs are expensive and it depends on theshortages, but the amount is not enough to solve the problem,"said Adel Abdel Maksoud, head of the pharmacy division at theCairo Chamber of Commerce.

TWITTER PHARMACY

In the meantime the companies say they have to stop offeringthe drugs which most cut into their profits. Some have alreadysent back shipments that were ordered before the float butarrived after, as selling them at the fixed prices would havecreated big losses. They all say they have to downsize and cutout certain drugs.

"We're working on a strategy to eliminate any product that'snot profitable. But companies that depend on unprofitableproducts will be forced to shut down now given the new currencyrate," said ITO Pharma's deputy general manager Mohamed Geoushy.

More life-saving drugs will soon disappear, he said.

His company is one of only two suppliers of cyclosporine, adrug used to prevent organ rejection during transplants. Itrecently stopped importing the drug, he said.

Pharmacists say patients have no choice but to resort to ablack market for once-common items like saline and glucose atprices often 10 times higher than the official caps and farbeyond the reach of most.

On Twitter, resourceful Egyptians have set up the hashtag"Twitter_Pharmacy" to swap medicines they cannot find in shops.Hospitals are using social media to advertise their needs.

"Every minister should have sat down with the governmentafter the float and discussed an emergency plan because it's acrisis if patients can't find life-saving medicines," said OsamaTahoon, general manager of medicine producer Julphar Egypt.

"We can give up sugar or tea, but we can't give upmedicine." (Additional reporting by Ben Hirschler in London, Editing byAngus MacSwan)

More News
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.